ARS Pharmaceuticals (SPRY) Share-based Compensation (2020 - 2026)

ARS Pharmaceuticals has reported Share-based Compensation for 7 years, with the latest figure at $65.0 million in Q1 2026.

• Quarterly Share-based Compensation rose 1126.88% year-over-year to $65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.0 million (up 502.63% YoY) and the FY2025 annual result came in at $42.4 million, up 3.16% from the prior year.
• Share-based Compensation advanced to $65.0 million in Q1 2026 per SPRY's latest filing, from -$530000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $65.0 million in Q1 2026 and troughed at -$530000.0 in Q4 2025.
• A 5-year average of $5.8 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 1953.49% in 2025, down 112.43% in 2025.
• Over 5 years, Share-based Compensation stood at $4.8 million in 2022, then slumped by 52.17% to $2.3 million in 2023, then surged by 87.14% to $4.3 million in 2024, then plunged by 112.43% to -$530000.0 in 2025, then jumped by 12364.15% to $65.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $65.0 million, -$530000.0, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.